Current approaches and challenges in monitoring treatment responses in breast cancer

doi:10.7150/jca.7047

Review

. 2014 Jan 5;5(1):58-68.

doi: 10.7150/jca.7047.

Current approaches and challenges in monitoring treatment responses in breast cancer

Affiliations

¹ 1. San Antonio Military Medical Center (SAMMC), 3551 Roger Brooke Dr., Ft. Sam Houston, TX 78234, USA.
² 2. Walter Reed National Military Medical Center (NMMC), 8901 Wisconsin Ave Bethesda, MD 20814, USA.
³ 3. Hadassah Medical Center, Kiryat Hadassah, POB 12000, Jerusalem, 91120, Israel.
⁴ 4. IU Health Goshen, 200 High Park Ave., Goshen, IN 46526, USA.
⁵ 5. Bon Secours Cancer Institute, 6505 West Broad St., Richmond, VA 23230, USA.

PMID: 24396498
PMCID: PMC3881221
DOI: 10.7150/jca.7047

Review

Current approaches and challenges in monitoring treatment responses in breast cancer

Lindsey J Graham et al. J Cancer. 2014.

. 2014 Jan 5;5(1):58-68.

doi: 10.7150/jca.7047.

Affiliations

¹ 1. San Antonio Military Medical Center (SAMMC), 3551 Roger Brooke Dr., Ft. Sam Houston, TX 78234, USA.
² 2. Walter Reed National Military Medical Center (NMMC), 8901 Wisconsin Ave Bethesda, MD 20814, USA.
³ 3. Hadassah Medical Center, Kiryat Hadassah, POB 12000, Jerusalem, 91120, Israel.
⁴ 4. IU Health Goshen, 200 High Park Ave., Goshen, IN 46526, USA.
⁵ 5. Bon Secours Cancer Institute, 6505 West Broad St., Richmond, VA 23230, USA.

PMID: 24396498
PMCID: PMC3881221
DOI: 10.7150/jca.7047

Abstract

Monitoring response to treatment is a key element in the management of breast cancer that involves several different viewpoints from surgery, radiology, and medical oncology. In the adjuvant setting, appropriate surgical and pathological evaluation guides adjuvant treatment and follow up care focuses on detecting recurrent disease with the intention of improving long term survival. In the neoadjuvant setting, assessing response to chemotherapy prior to surgery to include evaluation for pathologic response can provide prognostic information to help guide follow up care. In the metastatic setting, for those undergoing treatment, it is crucial to determine responders versus non-responders in order to help guide treatment decisions. In this review, we present the current guidelines for monitoring treatment response in the adjuvant, neoadjuvant, and metastatic setting. In addition, we also discuss challenges that are faced in each setting.

Keywords: Adjuvant; Breast cancer; Future directions; Metastatic; Neo-adjuvant; Treatment monitoring.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Cited by

AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.
Garczyk S, von Stillfried S, Antonopoulos W, Hartmann A, Schrauder MG, Fasching PA, Anzeneder T, Tannapfel A, Ergönenc Y, Knüchel R, Rose M, Dahl E. Garczyk S, et al. PLoS One. 2015 Apr 15;10(4):e0122106. doi: 10.1371/journal.pone.0122106. eCollection 2015. PLoS One. 2015. PMID: 25875093 Free PMC article.
Invasive micropapillary carcinoma of the breast had poor clinical characteristics but showed no difference in prognosis compared with invasive ductal carcinoma.
Li G, Yang S, Yao J, Wang Z, Yao G, Liu M, Ye C. Li G, et al. World J Surg Oncol. 2016 Aug 5;14(1):207. doi: 10.1186/s12957-016-0960-z. World J Surg Oncol. 2016. PMID: 27492008 Free PMC article.
Breast Cancer with Increased Drug Resistance, Invasion Ability, and Cancer Stem Cell Properties through Metabolism Reprogramming.
Chong KH, Chang YJ, Hsu WH, Tu YT, Chen YR, Lee MC, Tsai KW. Chong KH, et al. Int J Mol Sci. 2022 Oct 25;23(21):12875. doi: 10.3390/ijms232112875. Int J Mol Sci. 2022. PMID: 36361665 Free PMC article.
Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI.
Andreassen MMS, Goa PE, Sjøbakk TE, Hedayati R, Eikesdal HP, Deng C, Østlie A, Lundgren S, Bathen TF, Jerome NP. Andreassen MMS, et al. MAGMA. 2020 Apr;33(2):317-328. doi: 10.1007/s10334-019-00778-8. Epub 2019 Sep 27. MAGMA. 2020. PMID: 31562584 Free PMC article.
Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
Hing JX, Mok CW, Tan PT, Sudhakar SS, Seah CM, Lee WP, Tan SM. Hing JX, et al. Breast. 2020 Aug;52:95-101. doi: 10.1016/j.breast.2020.05.005. Epub 2020 May 20. Breast. 2020. PMID: 32485607 Free PMC article.

See all "Cited by" articles

References

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41. doi:10.3322/caac.21149. - PubMed
1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92. doi:10.1056/NEJMoa050518. - PubMed
1. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012. doi:10.1016/S0140-6736(12)61963-1. - PMC - PubMed
1. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ. et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6. doi:10.1200/JCO.2007.10.8399. - PubMed
1. Ploos van Amstel FK, van den Berg SW, van Laarhoven HW, Gielissen MF, Prins JB, Ottevanger PB. Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer. 2013. doi:10.1007/s00520-013-1764-0. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov

[1] Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41. doi:10.3322/caac.21149. - PubMed

[2] Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41. doi:10.3322/caac.21149. - PubMed

[3] Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92. doi:10.1056/NEJMoa050518. - PubMed

[4] Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92. doi:10.1056/NEJMoa050518. - PubMed

[5] Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012. doi:10.1016/S0140-6736(12)61963-1. - PMC - PubMed

[6] Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012. doi:10.1016/S0140-6736(12)61963-1. - PMC - PubMed

[7] Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ. et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6. doi:10.1200/JCO.2007.10.8399. - PubMed

[8] Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ. et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6. doi:10.1200/JCO.2007.10.8399. - PubMed

[9] Ploos van Amstel FK, van den Berg SW, van Laarhoven HW, Gielissen MF, Prins JB, Ottevanger PB. Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer. 2013. doi:10.1007/s00520-013-1764-0. - PubMed

[10] Ploos van Amstel FK, van den Berg SW, van Laarhoven HW, Gielissen MF, Prins JB, Ottevanger PB. Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer. 2013. doi:10.1007/s00520-013-1764-0. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Current approaches and challenges in monitoring treatment responses in breast cancer

Affiliations

Current approaches and challenges in monitoring treatment responses in breast cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical